Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology: Poised For A Lift With Combinations
12:42pm, Monday, 20'th Apr 2026
Kura Oncology, Inc. remains a Buy, driven by ziftomenib's launch and promising combination trial data in AML. Ziftomenib's initial single-agent results are modest, but combination regimens (notably KO
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
11:26am, Monday, 20'th Apr 2026
Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
08:27am, Monday, 20'th Apr 2026
Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
Kura Oncology (NASDAQ:KURA) Trading Up 9.7% – Here’s What Happened
03:59am, Sunday, 19'th Apr 2026
Shares of Kura Oncology, Inc. (NASDAQ: KURA - Get Free Report) were up 9.7% during mid-day trading on Friday. The stock traded as high as $9.81 and last traded at $9.8030. Approximately 578,462 shares
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy
Kura Oncology, Inc. $KURA Shares Bought by SG Americas Securities LLC
05:05am, Tuesday, 07'th Apr 2026
SG Americas Securities LLC grew its stake in Kura Oncology, Inc. (NASDAQ: KURA) by 214.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 03'rd Apr 2026
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the trea
Kura Oncology: Commercialization In AML Presents Asymmetric Upside
08:15am, Thursday, 02'nd Apr 2026
Kura Oncology (KURA) is reiterated as a Strong Buy, leveraging Komzifti's differentiated safety profile and substantial cash position for asymmetric upside. KURA's 2026 revenue expectations are achiev
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:02pm, Thursday, 12'th Mar 2026
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology Q4 Earnings Call Highlights
04:49am, Saturday, 07'th Mar 2026
Kura Oncology (NASDAQ: KURA) executives used the company's fourth-quarter and fiscal 2025 earnings call to highlight what CEO Troy Wilson called a "defining year," driven by the FDA approval of Komzif
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 06'th Mar 2026
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the trea
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss
01:52am, Friday, 06'th Mar 2026
Kura Oncology, Inc. (NASDAQ: KURA - Get Free Report) gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously clos
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
12:45pm, Thursday, 05'th Mar 2026
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
